Anamorelin Study for Advanced Pancreatic Cancer

Metastatic Pancreatic Cancer Clinical Trial

Official title:

A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04844970
• Other study ID #: LHMC 20193054
• Status: Recruiting
• Phase: Phase 2
• Start date: April 1, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: Lahey Clinic
• Contact: Essence D Maston, PhD
• Phone: 7817443495
• Email: Essence.D.Maston[@]lahey.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day

Description:

Anorexia and cachexia are common clinical sequelae of uncontrolled, metastatic cancer. These effects can impair physical function, reduce quality of life, impair tolerability of anticancer therapy, and reduce survival. Anorexia and cachexia are especially challenging problems in patients diagnosed with metastatic pancreatic cancer. With an annual incidence approaching 50,000 patients in the U.S. alone, pancreatic cancer has an annual mortality of approximately 40,000 patients with most individuals succumbing to their disease within two years. Between 70-80% of patients with metastatic pancreatic cancer experience cancer cachexia, which has been associated with reduced survival, increased risk of disease progression, and impaired chemotherapy tolerance.

Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. Several randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer.

The study is a randomized, placebo controlled multicenter, Phase II trial to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 patients with be enrolled in a 1:1 randomization to anamorelin HCL 100mg per day given concurrently with first-line chemotherapy compared to chemotherapy alone. Patients randomized to anamorelin HCL will take it daily for 24 weeks starting one day prior to chemotherapy. All patients will undergo an assessment by a certified nutritionist at or prior to their first cycle of chemotherapy. Both body weight and appetite will be measured at enrollment as well as at the initiation of chemotherapy. Patients will be stratified by degree of weight loss in the six months prior to enrollment, choice of first-line chemotherapy, and by baseline score of 5-item Anorexia Symptom Scale.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2024
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed written informed consent

2. Female or male =18 years of age

3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) unresectable or metastatic pancreatic adenocarcinoma

4. Body mass index < 20 kg/m2 with involuntary weight loss or >5% within 6 months prior to screening

5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of = 17 points on the 5-item Anorexia Symptom Scale and = 37 points on the 12-item FAACT A/CS

6. Subjects eligible to receive first line palliative chemotherapy

7. ECOG performance status 0 or 1 at screening

8. Acceptable hepatic function as defined by total bilirubin < 1.6 mg/dl unless associated with Gilbert syndrome, then total bilirubin < 2 x ULN. AST (SGOT) and ALT (SGPT) = 2.5 x ULN or if hepatic metastases are present = 5 x ULN

9. Appropriate treatment with pancreatic enzyme replacement prior to trial initiation

10. Female subjects shall be:

1. of non-childbearing potential or

2. of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product.

11. The patient must be willing and able to comply with the protocol tests and procedures All inclusion criteria will be checked at screening visit (Visit 1).

Exclusion Criteria:

1. Patient with other forms of pancreatic cancer (e.g. neuroendocrine tumors)

2. Patient undergoing major surgery within 4 weeks of randomization or plans to undergo major surgery during study period.

3. Women who are pregnant or breastfeeding

4. Patient with alternative cause of cachexia as determined by the investigator including: a) severe COPD requiring O2, b) severe heart failure (NYHA Class III- IV), c) second malignancy

5. Reversible causes of reduced food intake as determined by the investigator including but not limited to: severe mucositis (>=NCI CTCAE grade 3), mechanical obstruction, severe nausea, vomiting, or diarrhea (>=NCI CTCAE grade 3)

6. Patient unable to swallow pills

7. Patient with history of bariatric surgery, gastrectomy, or malabsorption disorder (gastritis, esophagitis)

8. Patient with recent use of CYP3A4 inhibitors

9. Patient with current daily use of therapies that may increase the QRS interval durations

10. Patient currently taking medications/compounds intended to increase appetite or decrease weight loss (e.g. testosterone, megestrol acetate, cannabis products, methylphenidate, corticosteroids, olanzapine, mirtazapine (allowed if >4 weeks of use as therapy for depression)

11. Patient with current use of tube feeding or parenteral feeding

12. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites

13. Patient with uncontrolled or significant cardiovascular disease, including:

1. History of myocardial infarction within the past 3 months

2. A-V block of second or third degree (may be eligible if currently have a pacemaker)

3. Unstable angina

4. Congestive heart failure within the past 3 months, if defined as NYHA class III-IV

5. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)

6. Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)

7. Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic

14. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus

15. Patient with uncontrolled pain.

16. Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study

17. Enrollment in a previous study with anamorelin HCl

18. Enrollment in another clinical trial during the time of this trial.

Related Conditions & MeSH terms

• Metastatic Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Anamorelin Hydrochloride
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
• Placebo
Anamorelin placebo

Locations

Country	Name	City	State
United States	Lahey Hospital & Medical Center	Burlington	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Lahey Clinic	Helsinn Healthcare SA, Quartesian LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Unplanned visits	number of unplanned visits for symptom management as defined by unscheduled clinic visits, emergency department visits, or hospitalizations	from baseline to week 25 (end of the study)
Other	Chemotherapy Dose change	Percent change in dose intensity of chemotherapy as defined by percent reduction in anticipated chemotherapy dose as determined y the treating physician	from baseline to week 13
Primary	Weight change	demonstrate superiority of anamorelin HCl dosed at 100mg per day vs. placebo on body weight gain and improvement in anorexia symptoms in patients undergoing first-line chemotherapy for incurable pancreatic cancer.	25 weeks
Secondary	Anorexia Questionnaire	Absolute change in the FAACT 5 item Anorexia Symptom Score from baseline at week	from baseline to week 13
Secondary	Survival	Overall Survival	25 weeks
Secondary	Radiologic Response to Chemotherapy	Chemotherapy response will be evaluated by RECIST criteria	from baseline to week 13
Secondary	Weight gain		from baseline to week 25 (end of the study)
Secondary	Fatigue Questionnaire	Change in FACIT-F questionnaire, fatigue subscale	from baseline to week 13
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	expected toxicities for Chemotherapies (FOLFIRINOX and Gemcitabine/Nab-Paclitaxel) will be assessed by CTCAE v5.0	from baseline to week 25 (end of study)
Secondary	AEs	AEs that are related to the drug	from baseline to week 25 (end of study)